MWMarie Westergaard‐Nielsen

Marie Westergaard‐Nielsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie Westergaard‐Nielsen has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Elo Andersen

    Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark

    7 shared publications
  • Stine Rosenkilde Larsen

    Department of Pathology, Odense University Hospital, Odense, Denmark

    7 shared publications
  • Benedicte Parm Ulhøi

    Department of Pathology, Aarhus University Hospital, Aarhus, Denmark

    6 shared publications
  • Claus Andrup Kristensen

    Department of Oncology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark

    6 shared publications
  • Henrik Jacobsen

    Department of Otorhinolaryngology, Head and Neck Surgery, Aalborg University Hospital, Aalborg, Denmark

    6 shared publications
  • Jesper Grau Eriksen

    Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

    6 shared publications

Latest Publications

  • A Protocolled Implementation of Upfront Ultrasound, A Stepwise Pre‐Operative Imaging Regimen in Primary Hyperparathyroidism

    by Vanessa Dedeic, Oke Gerke, Mette Bay, Jes Sloth Mathiesen, Marie Westergaard‐Nielsen, Sys Vestergaard, Paw Christian Holdgaard, Viveque Egsgaard Nielsen, Sanne Høxbroe Michaelsen

    Objective: To evaluate the sensitivity of a stepwise preoperative imaging regimen for patients with primary hyperparathyroidism. Study design: Prospective cohort study. Setting: A high‐volume tertiary referral center for parathyroidectomy. Methods: Patients with primary hyperparathyroidism referred for parathyroidectomy underwent surgeon‐performed ultrasound as the primary preoperative imaging examination. The diagnostic confidence of the examiner on a scale from 0 to 3 determined whether additional imaging was acquired. If ultrasound identified an enlarged parathyroid gland with certainty (score 3), the patient was booked directly for surgery. If the confidence score was <3, the patient underwent either parathyroid scintigraphy or 18F‐choline PET/CT. The gold standard was the intraoperative location of pathological parathyroid glands combined with biochemical cure ≥6 months after surgery. The primary endpoint was the sensitivity of the stepwise imaging regimen per patient, irrespective of the number of acquired imaging modalities. Secondary endpoints were the sensitivity per gland and the sensitivity of the imaging regimen if the cut‐off for additional imaging had been a confidence score of 1 or 2. Results: Upfront ultrasound spared 49 of 99 patients (49.5%) from additional imaging and correctly localized ≥1 pathological parathyroid gland in 98.0% of patients [95% CI 92.9‐99.8]. The per‐gland sensitivity was 92.5% [95% CI 84.8‐1.0]. When changing the cut‐off to a confidence score of 2, the per‐patient sensitivity remained 98.0% [95% CI 92.9‐99.8]. Conclusion: Our study demonstrates that a stepwise imaging regimen based on upfront ultrasound by an experienced examiner can substantially reduce the number of radiation‐based supplemental scans, while maintaining a high sensitivity.

  • Open Access

    Epidemiology, outcomes, and prognostic factors in submandibular gland carcinomas: a national DAHANCA study

    by Marie Westergaard-Nielsen, Christian Godballe, Jesper Grau Eriksen, Stine Rosenkilde Larsen, Katalin Kiss, Tina Agander, Benedicte Parm Ulhøi, Birgitte Wittenborg Charabi, Tejs Ehlers Klug, Henrik Jacobsen, et al.

    Purpose: The aim of this study is to present incidence, histological subtypes, survival rates, and prognostic factors based on a national cohort of patients with salivary gland carcinoma.Methods: All Danish patients with submandibular gland carcinoma diagnosed from 1990 to 2015 (n = 206) were included and analyzed following histological re-evaluation. Data were collected by the Danish Head and Neck Cancer Group (DAHANCA). Overall, disease-specific and recurrence-free survival were evaluated. Prognostic factors were analyzed with multivariate Cox Hazard Regression.Results: The study population consisted of 109 (53%) men and 97 (47%) women, median age 62 years (range 11–102). Adenoid cystic carcinoma was the most frequent subtype (50%). Tumour classification T1/T2 (75%) and N0 (78%) was most frequent. The mean crude incidence was 0.17/100,000/year. Most patients (n = 194, 94%) were treated with primary surgery, and 130 (67%) received postoperative radiotherapy. The 5- and 10-year survival rates were for overall survival 64% and 41%, disease-specific survival 74% and 61%, and recurrence-free survival 70% and 56%, respectively. Survival rates were higher for adenoid cystic carcinoma compared to other subtypes, but the difference was not significant in multivariate analysis. Recurrence occurred in 69 patients, and 37 (53.6%) of them had recurrence in a distant site. Advanced T-classification and regional lymph-node metastases had significant negative impact on survival rates.Conclusion: The incidence of submandibular gland carcinoma in Denmark was 0.17/100,000/year and stable during the time period. The most frequent subtype was adenoid cystic carcinoma. Half of the recurrences presented in a distant site, and multivariate analysis confirmed that advanced stage was independent negative prognostic factor for recurrence and survival.


  • Reply to Letter to the Editor regarding “In reference to Surgical treatment of the neck in patients with salivary gland carcinoma”

    by Marie Westergaard‐Nielsen, Christian Godballe, Jesper Grau Eriksen, Stine Rosenkilde Larsen, Katalin Kiss, Tina Agander, Benedicte Parm Ulhøi, Birgitte Wittenborg Charabi, Tejs Ehlers Klug, Henrik Jacobsen, et al.

  • Reply to Letter to the Editor regarding "Elective neck dissection and its extent in Salivary gland cancers: A Dilemma"

    by Marie Westergaard‐Nielsen, Christian Godballe, Jesper Grau Eriksen, Stine Rosenkilde Larsen, Katalin Kiss, Tina Agander, Benedicte Parm Ulhøi, Birgitte Wittenborg Charabi, Tejs Ehlers Klug, Henrik Jacobsen, et al.


  • Prognostic scoring models in parotid gland carcinoma

    by Marie Westergaard‐Nielsen, Sören Möller, Christian Godballe, Jesper Grau Eriksen, Stine Rosenkilde Larsen, Katalin Kiss, Tina Agander, Benedicte Parm Ulhøi, Birgitte Charabi, Tejs Ehlers Klug, et al.

    Background: The aim was to identify prognostic factors and test three prognostic scoring models that predicted the risk of recurrence in patients with parotid gland carcinoma.Methods: All Danish patients with parotid gland carcinoma, treated with curative intent, from 1990 to 2015 (n = 726) were included. Potential prognostic factors were evaluated using Cox regression and competing risk analyses. The concordance of each prognostic model was estimated using Harrel's C index.Results: The study population consisted of 344 men and 382 women, with a median age of 63 years. Age above 60 years, high grade histology, T3/T4 tumor, regional lymph node metastases, and involved surgical margins were all associated with a significant reduction in recurrence‐free survival. The prognostic model that agreed best with actual outcomes had a C‐index of 0.76.Conclusion: Prognostic scoring models may improve individualized follow‐up strategies after curatively intended treatment for patients with parotid gland carcinoma.


  • Surgical treatment of the neck in patients with salivary gland carcinoma

    by Marie Westergaard‐Nielsen, Christian Godballe, Jesper Grau Eriksen, Stine Rosenkilde Larsen, Katalin Kiss, Tina Agander, Benedicte Parm Ulhøi, Birgitte Wittenborg Charabi, Tejs Ehlers Klug, Henrik Jacobsen, et al.

    Background: Elective neck dissection (END) in patients with salivary gland carcinoma is controversial and there are no universally accepted guidelines.Methods: Patients were identified from the Danish Head and Neck Cancer Group. Between 2006 and 2015, 259 patients with primary salivary gland carcinoma were treated with END. Variables potentially associated with regional metastases were analyzed using logistic regression. Neck recurrence‐free survival was calculated using the Kaplan–Meier method.Results: Occult metastases were found in 36 of the patients treated with END (14%) and were particularly frequent among patients with T3/T4 tumors and high‐grade histology tumors. In multivariate analyses, high‐grade histology and vascular invasion were associated with occult metastases.Conclusion: We recommend END of levels II and III for patients with high‐grade or unknown histological grade tumors, and for T3/T4 tumors. Levels I, II, and III should be included in END in patients with submandibular, sublingual, or minor salivary gland carcinomas.


  • Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome

    by Marie Westergaard-Nielsen, Christian Godballe, Jesper Grau Eriksen, Stine Rosenkilde Larsen, Katalin Kiss, Tina Agander, Benedicte Parm Ulhøi, Birgitte Charabi, Tejs Ehlers Klug, Henrik Jacobsen, et al.

    Purpose Salivary gland carcinoma is a rare disease and studies on epidemiology and outcome require data collection over many years. The aim of this study is to present an update of incidence rates, anatomical sites, histological subtypes, and survival rates based on the Danish national cohort of salivary gland carcinoma patients. Methods Data from all Danish patients with salivary gland carcinoma diagnosed from 1990 to 2015 (n = 1601) were included and analyzed following histological reevaluation and reclassification. Overall, disease-specific, and recurrence-free survival were evaluated. Prognostic factors were analyzed with multivariate Cox Hazard Regression. Results The study population consisted of 769 men and 832 women, median age 62 years (range 6–102). The most frequent anatomic site was the parotid gland (51.8%). Adenoid cystic carcinoma was the most common subtype (24.7%). The majority had tumor classification T1/T2 (65.3%). The mean crude incidence was 1.2/100.000/year with an increase of 1.5% per year. There was no increase in age-adjusted incidence. The 5-, 10-, and 20-year survival rates were for overall survival 68, 52, and 35%, for disease-specific survival, 77, 69, and 64%, and for recurrence-free survival, 75, 64, and 51%, respectively. Age, high-grade histological subtype, advanced T-classification, cervical lymph node metastases, vascular invasion, and involved surgical margins had significantly negative impact on survival rates. Conclusion The age-adjusted incidence has been stable for a period of 26 years. Multivariate analysis confirmed that histological grade, advanced stage, involved surgical margins and vascular invasion are independent negative prognostic factors. Survival rates were stationary compared to earlier reports.


  • Open Access

    Elective neck dissection in patients with salivary gland carcinoma: A systematic review and meta‐analysis

    by Marie Westergaard‐Nielsen, Tine Rosenberg, Oke Gerke, Anne‐Kirstine Dyrvig, Christian Godballe, Kristine Bjørndal

    Objective Elective neck dissection in patients with salivary gland carcinoma and clinical negative lymph nodes is controversial. Reported proportion of occult nodal metastases vary with histological subtype, tumour classification and preoperative diagnostic methods. This is a systematic review and meta‐analysis on the role of END in salivary gland carcinoma. Methods A search in PubMed, Embase, and Cochrane was performed. Original articles in English with data on tumour characteristics, clinical and pathological N‐classification, and neck dissection were included. Reporting Items for Systematic Reviews and Meta‐analyses were followed. Random effect modelling was performed to pool the data. Meta‐analysis of proportions was performed for occult metastases overall, for T3/T4 versus T1/T2 tumours, and for tumours with high grade versus low grade histology. Heterogeneity across studies was assessed with I‐squared statistics. Results We included 22 articles in the qualitative synthesis and meta‐analysis. The pooled proportion of occult metastases was 21%. In patients with T3/T4 tumour, the pooled proportion of occult metastases was 36%, and in patients with high grade histology it was 34%. Most studies concluded that END should be performed in patients with advanced T‐classification and high‐grade histology tumours. Nine studies assessed occult metastases per level. Conclusion The overall occult metastases proportion does not require END in all patients with salivary gland carcinoma. We recommend END in patients with high grade or unknown histology or T3/T4 tumours. END should involve level II and III, and level I should be included in tumours in the submandibular gland, sublingual gland, and minor oral salivary glands.


  • Up-front F18-FDG PET/CT in suspected salivary gland carcinoma

    by Marie Westergaard-Nielsen, Max Rohde, Christian Godballe, Jesper G. Eriksen, Stine Rosenkilde Larsen, Oke Gerke, Nina Nguyen, Mie K. Nielsen, Anne L. Nielsen, Anders Thomassen, et al.

    To investigate whether a 18F-FDG PET/CT (PET/CT)-based diagnostic strategy adds decisive new information compared to conventional imaging in the evaluation of salivary gland tumours and the detection of cervical lymph node metastases, distant metastases, and synchronous cancer in patients with salivary gland carcinoma.


  • Oncocytic carcinoma of the salivary glands: A Danish national study

    by Marie Westergaard-Nielsen, Christian Godballe, Lisbeth Juhler Andersen, Hanne Primdahl, Claus A. Kristensen, Elo Andersen, Kristine Bjørndal